SGLT2 inhibitors × adverse events & safety

SynthesisFrontiers in endocrinology2023

Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.

Lu Chen et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 12,990 people · 2023

Randomised comparison

Raised adverse events & safety

2.1×1.2× to 3.8×

Bigger than 8 in 10 for adverse events & safety

As reported

OR 2.11, 95% CI 1.20–3.79

One number in the abstract

the abstract, start to end

for urinary tract infections (UTI, OR 2.11, 95%CrI 1.20 to 3.79, 87.2%),

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
OR 2.111.20–3.79
SGLT2 inhibitorsAdverse events & safety

SGLT2 inhibitors × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

9 papers cite it

2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 38027214